Eliptica has received an award through Innovate UK's Biomedical Catalyst programme in 2026.

Biomedical Catalyst supports UK businesses developing innovative solutions to health and healthcare challenges. The published 2025 industry-led R&D small projects competition was open to individual businesses and collaborations.

Eliptica is a Bio-AI spin-out from the Francis Crick Institute in London. Its team brings together expertise in biochemistry, metabolism, high-throughput proteomics and machine learning, with the aim of translating proteomics into routine clinical practice.

Further information

• UKRI Biomedical Catalyst programme information